Articles tagged with Cancer Medication
A recent review highlights the growing concern of counterfeit medicines being sold online and turning up in legitimate supply chains. The study found that nearly 75 billion dollars worth of fake drugs are sold globally each year, putting millions of lives at risk.
Researchers evaluated a teaching program for breaking bad news to patients, finding that medical students reported improved comfort in addressing difficult topics. The program involved videotaped sessions with standardized patients and post-interview discussions, which were found to be highly beneficial.
A newly approved drug for metastatic melanoma has nearly doubled median survival times, changing the way this deadly form of skin cancer is treated. The drug, Zelboraf, blocks a mutated BRAF protein and has been shown to have a significant impact on patient outcomes.
A new melanoma drug, vemurafenib (Zelboraf), has been shown to nearly double the median overall survival of patients with metastatic melanoma. The Phase 2 trial found that 53% of patients responded to treatment and experienced improved survival rates.
Researchers at UCSF have discovered a new class of drugs that target the mTOR protein, which is hyperactive in many forms of cancer. The new drugs block mTOR more completely than previous ones, effectively hobbles cancer cells and prevents metastasis.
Researchers have developed a reformulated imatinib that prevents and reverses morphine tolerance in rats, offering new hope for treating chronic intractable pain. The study's findings suggest the potential to reduce debilitating side effects associated with morphine use.
Researchers have discovered that adding hydroxychloroquine to various cancer therapies can enhance their effectiveness in treating treatment-resistant cancers. By blocking autophagy, a process by which cells recycle damaged proteins, the combination of chemotherapy and HCQ can lead to improved outcomes for patients.
Researchers at Wake Forest University used video game graphics processing units (GPUs) to simulate human cell behavior, revealing new insights into the telomerase enzyme and its role in cancer. The study's findings could lead to the development of new cancer treatments by targeting the enzyme.
A new strategy combining carbon nanoparticles with chemotherapy and radiation therapy shows significant potential in treating head-and-neck cancers. The treatment uses nanoparticles to encapsulate chemotherapeutic drugs, delivering them directly to cancer cells.
Researchers sequenced the complete genome of an immortal Tasmanian devil and its transmissible cancer, providing insights into how the disease spread rapidly through the population. The study identified over 17,000 mutations in the cancer genome, which may lead to therapeutic strategies against cancer genes.
Four new drugs offer innovative methods of action against prostate cancer, including bone protective agents, hormone treatments and immunotherapy. These advancements could extend survival prognosis and potentially turn prostate cancer into a chronic disease.
Salk researchers have identified a new potential drug target for treating certain types of lung cancer. By blocking the activity of the enzyme IKK2, which regulates inflammation, the study found that tumors grew more slowly and animals lived longer.
Researchers at the University of Texas at Austin have developed a molecule that can bind to DNA for up to 16 days, making it a promising step towards creating drugs that can target rogue DNA. This breakthrough could lead to new treatments for genetic diseases, cancer, and retroviruses like HIV.
The European Society for Paediatric Oncology (SIOPE) is advocating for policy changes to address the negative impact of EU legislation on childhood cancer treatment. The current directive has increased bureaucracy and administration, making it time-consuming and expensive to conduct clinical trials.
Scientists at Dana-Farber Cancer Institute have discovered a subtype of ovarian cancer that is susceptible to anti-angiogenic drugs, which block blood vessel formation. The subtype accounts for approximately one-third of all serous ovarian cancers and may benefit from therapies currently being tested in other cancers.
Researchers have gained a better understanding of two key proteins that control cell division, which could lead to the development of new drugs to stop cancerous cells multiplying. This discovery could also help optimise personalised chemotherapy treatments and limit side effects associated with some chemotherapy drugs.
A new algorithm, R-SAP, transforms complex RNA sequence data into usable content for biologists and clinicians, enabling personalized cancer medicine. The pipeline accurately characterizes gene transcripts in cancer samples and provides information on splice variants, biomarkers, and chimeric RNAs.
A new study found that short fasting cycles can work as well as chemotherapy to treat cancer in mice, and combining both greatly improves survival rates. Fasting alone also effectively treated a majority of cancers tested in animals, including those from human cells.
The partnership aims to reduce cancer health disparities in Hispanic populations through outreach education projects and pilot research studies. The collaboration has already learned valuable lessons, including the importance of a patient-centered approach and culturally specific dissemination routes for information.
Researchers at Van Andel Research Institute have discovered a predictive marker for patient sensitivity to MET inhibitors in glioblastoma. The study may lead to the development of improved therapies for this deadly brain cancer.
A new analysis found that targeted cancer drugs increase the risk of fatal side effects, including bleeding and heart attacks. The study recommends caution when using these drugs in patients at high risk for complications.
Researchers found that Toca 511 eliminates tumors in most animals after dosing with 5-FC, providing a dramatic survival benefit. The treatment was well-tolerated and did not cause toxicity over the six-month protocol.
Lab tests have found that silver compounds are as toxic to cancer cells as platinum-based drug Cisplatin, but may be less toxic to healthy human cells. Researchers hope to develop next-generation chemotherapy drugs using these findings.
A new study reveals substantial differences in follow-up surgeries for women with breast cancer, affecting cancer recurrence and overall survival rates. The research highlights the need for quality measures to compare breast cancer surgical outcomes among surgeons and hospitals.
Researchers at Boston University have developed a unique material and drug delivery mechanism that can slow the release of anti-cancer drugs over months. The system uses a biocompatible, porous polymer material with air pockets to prevent immediate release in case of water flooding.
The phase III clinical trial shows that men treated with MDV3100 had a median survival of 18.4 months compared to 13.6 months for those receiving placebo, resulting in a 37% reduction in mortality risk. This breakthrough treatment tackles drug-resistant prostate cancer, providing new hope for patients.
Researchers have identified a new family of hypoxic regulator proteins that malfunction when dysregulated, contributing to the progression of serious diseases like cancer. This discovery may lead to the development of novel drug therapeutics to combat cancer and other oxygen-related disorders.
A team of UT researchers has developed a novel physical form of proteins that can improve treatments for cancer and other diseases by overcoming the major challenge of drug delivery. The new approach enables safe, easy, and effective delivery of drugs to patients, revolutionizing treatment of cancer, arthritis, and infectious disease.
BWH researchers created a new method for controlled drug release utilizing air as a removable barrier. The rate of drug release correlates with the removal of the air pocket, enabling extended periods of controlled delivery.
Researchers identified a molecular loop between mutated Kras, NF-κB, and IL-1α, which perpetuates inflammation, tumor growth, and poor survival in pancreatic cancer. This discovery suggests targeting IL-1α as a potential treatment avenue to block the elusive target of mutated Kras.
Researchers found that Avastin and Sutent, anti-angiogenesis drugs, increase cancer stem cells in breast tumors, fueling growth and spread. The study suggests combining these drugs with cancer stem cell inhibitors may enhance treatment effectiveness.
A study published in the Journal of the National Cancer Institute found that telephone counseling services doubled the odds of quitting smoking among Chinese-, Korean-, and Vietnamese-speaking smokers. In contrast, a second study on bupropion SR showed promise for African American light smokers during medication phase but lacked long-t...
Researchers found that blocking HSP90 activity renders protected proteins vulnerable to destruction, slowing the growth of MIF-expressing breast tumors. HSP90 inhibitors also showed promise in slowing leukemia cell growth driven by hyperactive JAK2 enzyme versions.
A three-year clinical trial shows dutasteride delays prostate cancer disease progression by 38% compared to placebo, while also reducing anxiety. The study suggests a viable treatment option for men with low-risk disease, offering a safer alternative to aggressive local treatment.
A Kansas State University researcher is studying foods and dietary supplements that may reduce the risk of prostate cancer. Finasteride and dutasteride drugs, which lower testosterone levels, have shown promise in reducing prostate cancer incidence but may lead to worse outcomes for those who develop the disease.
Researchers at IMIM have discovered a new mechanism of resistance to colon cancer treatment, where a mutation in the EGFR oncogene causes resistance to drug cetuximab. The finding has significant clinical implications and opens up possibilities for using alternative treatments like panitumumab.
A new class of nanoparticles has been developed to prevent premature drug release and ensure targeted delivery to tumors. The dual-responsive boronate cross-linked micelles (BCMs) can release drugs in response to acidic environments or mannitol, minimizing premature release and maximizing tumor targeting.
Scientists have documented how ALK positive advanced non-small cell lung cancer becomes resistant to crizotinib, a previously effective treatment. Researchers now aim to develop combination therapies to tackle this resistance and improve patient outcomes.
Research at McGill University found that metformin reduces the cellular mutation rate and accumulation of DNA damage, a key mechanism in carcinogenesis. The study suggests that metformin's anti-cancer effects may be linked to its ability to reduce reactive oxygen species production in mitochondria.
Researchers found that blocking the mutated BRAF protein in melanoma cells sets off a cellular cascade in other skin cells with pre-disposing mutations, leading to accelerated development of skin squamous cell carcinomas. The study provides molecular insight into this side effect and suggests strategies to prevent secondary tumors.
Researchers have sequenced the nuclear genome of Schistosoma haematobium, a parasitic worm linked to bladder cancer and HIV/AIDS. The discovery offers insights into how the parasite induces malignant bladder cancer and provides a biological roadmap for developing new disease interventions, including drugs and vaccines.
Researchers at Stanford University have used a computer algorithm to find markers that predict how deadly bladder cancer will be, offering faster and more accurate analysis of cancer risk. The test can be performed by someone with little training and may help identify patients with the most aggressive subtype before it becomes invasive.
Researchers found that regorafenib slowed tumor progression and lengthened patient lives by 29% compared to placebo. The median survival time increased from 5 months to 6.5 months, with a 23% reduced risk of cancer-related death.
Researchers found that combining lapatinib and trastuzumab improved pathologic complete response rates in early-stage HER2-positive breast cancer patients compared to single-agent treatment. The study suggests dual HER2 blockade as a more effective approach for patients with early, non-metastatic HER2 breast cancer.
MDC researchers found that both forms of therapy are highly effective against large tumors, but T-cell therapy also destroys the tumor blood vessel system, impeding nutrient supply and eradicating resistant tumor cells. This breakthrough may improve future clinical trials and cancer treatment
The American Cancer Society, Union for International Cancer Control, and Japanese Cancer Association are supporting the launch of a new open access journal. The journal aims to provide rapid publication of cutting-edge cancer research from global biomedical and clinical researchers.
A study by OHSU Knight Cancer Institute suggests that faulty proteins may be key to identifying new treatments for ovarian cancer. Researchers found that 41% of patients with early disease recurrence had abnormal levels of other proteins, opening up a new direction in treatment.
Researchers identify genetic alterations in T-ALL that work together to cause the devastating childhood cancer, providing new potential treatment strategies. The study reveals a dynamic interplay between Notch and PRC2 function, showing how deregulation of PRC2 fuels the development of T-ALL.
The foundation awarded $156,000 each to 18 new fellows and $100,000 to three Breakthrough Scientists recipients. The awards support novel ideas in cancer research, enabling the nation's most promising young scientists to pursue careers in cancer research.
Researchers identified genetic mutations in OATP1B1 and OATP1B3 proteins as the underlying cause of Rotor syndrome, a condition characterized by conjugated bilirubin buildup. Complete deficiency of these proteins can cause hypersensitivity to certain drugs and interrupt conjugated bilirubin reuptake into the liver.
A small clinical trial found that taking varenicline (Chantix) for four weeks before quitting increased tobacco-free rates by 27% compared to one week. Women showed the greatest improvement, reducing smoking by over 50%. The study suggests a longer treatment period may lead to better outcomes.
A recent study identified effective agents from approved drugs with anti-cancer activity in thyroid cancer cells, offering potential repurposing opportunities for aggressive recurrent or metastatic cases. The compounds found had potent activity across different therapeutic categories and modes of action.
A new downloadable tool from the University of Colorado Cancer Center guides cancer survivors through a personalized exercise plan, helping them set goals and track progress. The program aims to overcome common challenges faced by cancer patients, including fatigue and self-doubt.
A clinical trial led by Drs. Amit Oza and Timothy Perren found that treating ovarian cancer with bevacizumab (
A new phase 3 clinical trial shows that targeted therapy bevacizumab effectively delays the progression of advanced ovarian cancer. Patients with newly diagnosed advanced ovarian cancer can now benefit from an additional treatment option, alongside surgery and chemotherapy.
Researchers identify PDHK enzyme as a key player in cancer cell metabolism, enabling targeted anti-cancer therapy. Inhibiting PDHK activity slows tumor growth and reduces glucose uptake by cancer cells.
A new study by McMaster University researchers has found that certain proteins involved in cancer treatment can also combat antibiotic resistance. The study, led by Gerry Wright, screened 14 antibiotic-resistant molecules against 80 chemically diverse protein kinase inhibitors and identified potential repurposing opportunities.
A research team led by Dr. David Huntsman and Dr. Gregg Morin found that mutations in the DICER gene were responsible for rare, unrelated cancers, revealing a fundamental process underlying these tumors. The discovery has the potential to lead to new approaches to treating both rare and common cancers.
A Vanderbilt University team has created a new method to optically assess the response of cancer cells to a specific drug, using light to visualize metabolic pathways. The technique could enable real-time monitoring of tumor response and help doctors make timely treatment decisions.
A team of researchers found that raising levels of epoxyeicosatrienoic acids (EETs) in mice stimulated primary tumor growth and metastasis, suggesting potential risks for humans. EET antagonists may provide a new approach to preventing and treating cancer-related metastasis.